ALKS · Company research

Alkermes plc

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsALKSAlkermesQ4 2026

Alkermes expects to report results from its Phase 3 study of Alixorexton (ALKS 2680) for Idiopathic hypersomnia in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

Vibrance-3 Phase 2 completion in idiopathic hypersomnia · Clinical trial results (readout / topline data)

Drug

Alixorexton (ALKS 2680)

For

Idiopathic hypersomnia

Stage

Phase 3 · the last stage before a drug can be approved

When

Q4 2026 · the company gave a window, not a day

Source note

Q2 2026 earnings call: Vibrance-3 study completion expected in Q4 2026, with topline data to follow; split-dose arm still enrolling.

Checked

Checked by a person when it was added

Verify it

Source: finance.yahoo.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneALKSAlkermesQ4 2026

sNDA submission for LUMRYZ in idiopathic hypersomnia by year-end 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Alkermes (LUMRYZ (sodium oxybate ER) for idiopathic hypersomnia): a step in the program rather than a decision or a data readout.

More details

Entry

sNDA submission for LUMRYZ in idiopathic hypersomnia by year-end 2026 · Company milestone

Drug

LUMRYZ (sodium oxybate ER)

For

idiopathic hypersomnia

Stage

sNDA

When

Q4 2026 · the company gave a window, not a day

Source note

REVITALYZ Phase 3 topline PR (May 12, 2026), reiterated on Q2 2026 call. Note: contractual restriction bars marketing LUMRYZ for IH before March 1, 2028, regardless of approval timing.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALKSAlkermes2027

Alkermes expects to report results from its Phase 3 study of Alixorexton (ALKS 2680) for Narcolepsy type 1 and type 2 during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

Brilliance Phase 3 studies completion in narcolepsy (NT1/NT2) · Clinical trial results (readout / topline data)

Drug

Alixorexton (ALKS 2680)

For

Narcolepsy type 1 and type 2

Stage

Phase 3 · the last stage before a drug can be approved

When

2027 · the company gave a window, not a day

Source note

Q2 2026 earnings call: Phase 3 Brilliance studies (initiated April 2026) completion expected in 2027 (year-level precision only); alixorexton holds FDA Breakthrough Therapy designation in NT1.

Checked

Checked by a person when it was added

Verify it

Source: finance.yahoo.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

Trial resultsALKSAlkermesQ3 2026

Alkermes reported results from its Phase 1b study of ALKS 7290 for ADHD in Q3 2026 (Jul–Sep). The linked source has what the numbers showed.

More details

Entry

ALKS 7290 Phase 1b topline in ADHD · Clinical trial results (readout / topline data)

Drug

ALKS 7290

For

ADHD

Stage

Phase 1b

When

Q3 2026 · the company gave a window, not a day

Source note

Q2 2026 earnings call (Jul 28, 2026): top-line results expected by the end of the third quarter of 2026.

Checked

Checked by a person when it was added

Verify it

Source: finance.yahoo.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALKSAlkermesJul 13, 2026

Alkermes reported results from its Phase 2 study of alixorexton (ALKS 2680) for Narcolepsy type 1 and type 2 on Jul 13, 2026. The study met its main goal.

More details

Entry

Alixorexton long-term extension interim shows sustained wakefulness gains · Clinical trial results (readout / topline data)

Drug

alixorexton (ALKS 2680)

For

Narcolepsy type 1 and type 2

Stage

Phase 2 · the stage that tests whether the drug actually works

When

Jul 13, 2026

Source note

A planned interim analysis of the ongoing long-term extension study showed alixorexton produced sustained, clinically meaningful improvements on MWT and ESS across all dose groups in both narcolepsy type 1 and type 2, and was generally well tolerated.

Checked

Checked by a person when it was added

Verify it

Source: investor.alkermes.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceALKSAlkermesJun 17, 2026

Alkermes presented data on alixorexton (ALKS 2680) for Narcolepsy type 2 (NT2) at a medical meeting on Jun 17, 2026. The linked source has the details.

More details

Entry

Detailed positive Vibrance-2 alixorexton data presented at SLEEP 2026 · Data presented at a medical meeting

Drug

alixorexton (ALKS 2680)

For

Narcolepsy type 2 (NT2)

Stage

Phase 2 · the stage that tests whether the drug actually works

When

Jun 17, 2026

Source note

Alkermes presented detailed positive results from the Vibrance-2 phase 2 dose-ranging study of once-daily alixorexton in narcolepsy type 2, which met dual primary endpoints on MWT and ESS at week eight.

Checked

Checked by a person when it was added

Verify it

Source: investor.alkermes.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALKSAlkermesMay 12, 2026

Alkermes reported results from its Phase 3 study of LUMRYZ (sodium oxybate) extended-release for Idiopathic hypersomnia (IH) on May 12, 2026. The study met its main goal.

More details

Entry

Phase 3 REVITALYZ met primary endpoint for LUMRYZ in idiopathic hypersomnia · Clinical trial results (readout / topline data)

Drug

LUMRYZ (sodium oxybate) extended-release

For

Idiopathic hypersomnia (IH)

Stage

Phase 3 · the last stage before a drug can be approved

When

May 12, 2026

Source note

The randomized-withdrawal Phase 3 REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia hit its primary endpoint on Epworth Sleepiness Scale change (p<0.0001), with an sNDA planned by end of 2026. ALKS shares rose about 10%.

Checked

Checked by a person when it was added

Verify it

Source: investor.alkermes.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALKS headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to ALKS.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.